Diploma (LON:DPLM – Get Free Report) had its price target upped by research analysts at JPMorgan Chase & Co. from GBX 4,370 ($53.49) to GBX 4,420 ($54.10) in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 2.84% from the stock’s current price.
A number of other equities research analysts also recently issued reports on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 5,100 ($62.42) target price on shares of Diploma in a report on Friday, November 22nd. Shore Capital lowered shares of Diploma to a “hold” rating in a report on Tuesday, November 19th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of GBX 4,567.50 ($55.91).
Check Out Our Latest Research Report on Diploma
Diploma Stock Up 5.3 %
Insider Buying and Selling at Diploma
In other news, insider Chris Davies purchased 3,917 shares of Diploma stock in a transaction that occurred on Friday, December 20th. The stock was acquired at an average price of GBX 4,280 ($52.39) per share, for a total transaction of £167,647.60 ($205,199.02). Also, insider Johnny Thomson sold 26,794 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of GBX 4,536 ($55.52), for a total transaction of £1,215,375.84 ($1,487,608.13). 0.52% of the stock is owned by corporate insiders.
About Diploma
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Stories
- Five stocks we like better than Diploma
- Options Trading – Understanding Strike Price
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- 3 Small Caps With Big Return Potential
- How Do Stock Buybacks Affect Shareholders?
- What is the Hang Seng index?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.